prikaz prve stranice dokumenta Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA
  Preuzmi
PDF 158.5 KB
Znanstveni rad - Izvorni znanstveni rad
Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA
Psychiatry Research, 189 (2011), 1; 21-25. https://doi.org/10.1016/j.psychres.2010.11.021
Vuksan-Ćusa, Bjanka; Jakovljević, Miro; Šagud, Marina; Mihaljević Peleš, Alma; Marčinko, Darko; Topić, Radmila; Mihaljević, Sanea; Sertić, Jadranka

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Vuksan Ćusa, B., Jakovljević, M., Šagud, M., Mihaljević Peleš, A., Marčinko, D., Topić, R. ... Sertić, J. (2011). Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA. Psychiatry Research, 189. (1), 21-25. doi: 10.1016/j.psychres.2010.11.021

Vuksan Ćusa, Bjanka, et al. "Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA." Psychiatry Research, vol. 189, br. 1, 2011, str. 21-25. https://doi.org/10.1016/j.psychres.2010.11.021

Vuksan Ćusa, Bjanka, Miro Jakovljević, Marina Šagud, Alma Mihaljević Peleš, Darko Marčinko, Radmila Topić, Sanea Mihaljević i Jadranka Sertić. "Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA." Psychiatry Research 189, br. 1 (2011): 21-25. https://doi.org/10.1016/j.psychres.2010.11.021

Vuksan Ćusa, B., et al. (2011) 'Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA', Psychiatry Research, 189(1), str. 21-25. doi: 10.1016/j.psychres.2010.11.021

Vuksan Ćusa B, Jakovljević M, Šagud M, Mihaljević Peleš A, Marčinko D, Topić R, i sur.. Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA. Psychiatry Research [Internet]. 30.08.2011. [pristupljeno 25.11.2024.];189(1):21-25. doi: 10.1016/j.psychres.2010.11.021

B. Vuksan Ćusa, et al., "Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA", Psychiatry Research, vol. 189, br. 1, str. 21-25, Kolovoz 2011. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:887958. [Citirano: 25.11.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:887958
Podaci o radu
Naslov (engleski)Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with SGA
AutorBjanka Vuksan-Ćusa
AutorMiro Jakovljević
AutorMarina Šagud
AutorAlma Mihaljević Peleš
AutorDarko Marčinko
AutorRadmila Topić
AutorSanea Mihaljević
AutorJadranka Sertić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
There is accumulating evidence for an increased prevalence of metabolic syndrome (MetS) in bipolar patients, which is comparable to the prevalence of MetS in patients with schizophrenia. Hyperhomocysteinaemia has emerged as an independent and graded risk factor for the development of cardiovascular disease (CVD), which is, at the same time, the primary clinical outcome of MetS. The aim of this study was to ascertain if the presence of MetS was associated with hyperhomocysteinaemia in patients with bipolar disorder (N=36) and schizophrenia (N=46) treated with second-generation antipsychotics (SGA). MetS was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP-III) criteria and the cut-off point for hyperhomocysteinaemia was set up at 15μmoll(-1). Results of the study indicated that the presence of the MetS is statistically significantly associated with the elevated serum homocysteine in all participants. As hyperhomocysteinaemia has emerged as an independent risk factor for psychiatric disorder and CVD, it could be useful to include fasting homocysteine serum determination in the diagnostic panels of psychiatric patients to obtain a better assessment of their metabolic risk profile.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeZavršna verzija rukopisa prihvaćena za objavljivanje (postprint)
Naslov časopisaPsychiatry Research
Brojčani podacivol. 189, br. 1, str. 21-25
p-ISSN0165-1781
DOIhttps://doi.org/10.1016/j.psychres.2010.11.021
URN:NBNurn:nbn:hr:105:887958
Datum objave publikacije2011-08-30
URL dokumentahttps://doi.org/10.1016/j.psychres.2010.11.021
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-03-28 12:00:20